Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

Survival Rate:
Zanidatamab, a HER2-targeted bispecific antibody, achieved a 30-month overall survival rate of 59% in patients with HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).

Clinical Trial:
The data comes from an ongoing Phase 2 trial evaluating zanidatamab in combination with chemotherapy as a first-line treatment for HER2-expressing mGEA.

Efficacy:
The trial also reported a confirmed objective response rate (cORR) of 84%, a duration of response (DoR) of 18.7 months, and a median progression-free survival (mPFS) of 15.2 months.

Potential Treatment:
Zanidatamab shows promise as a foundational treatment for patients with HER2-positive mGEA, addressing a significant need for effective treatment options in this common tumor type.

Future Development:
Jazz Pharmaceuticals plans to continue advancing the clinical development program for zanidatamab, including a Phase 3 clinical trial for GEA.